

Supplementary Table 1. Baseline characteristics of eyes starting treatment with VEGF inhibitors and dexamethasone.

	VEGF inhibitors group	Dexamethasone group
Eyes, n	1406	267
Patients, n	973	204
Female, n (%)	368 (38)	75 (37)
Right Eye, n (%)	707 (50)	133 (50)
Pseudophakics, n (%)	251 (18)	75 (28)
Age years, mean (SD)	64 (13)	68 (11)
Diabetes duration years, mean (SD)	17 (10)	17 (10)
Diabetes type, %		
Type 1	13	4
Type 2	87	96
Diabetic retinopathy, %		
Mild	21	27
Moderate	39	34
Severe NPDR	22	13
PDR Non-High risk	12	17
PDR High risk	6	10
Baseline VA letters, mean (SD)	64.1 (18.5)	55.3 (20.8)
VA $\geq$ 69 letters, %	56	31
VA $\leq$ 35 letters, %	9	20
CST μ m, mean (SD)	398 (123)	456 (127)
IOP mmHg, mean (SD)	15 (4)	15 (4)
CSME grades, %		
Centre-involving	80	91
Non-centre involving	11	6
No CSME	9	3
n - Number, SD – Standard Deviation, NPDR – Non-Proliferative Diabetic Retinopathy, PDR – Proliferative Diabetic Retinopathy, VA – Visual Acuity, CST – Central Subfield Thickness, IOP – Intraocular pressure, CSME – Clinically Significant Macular Edema, VEGF – Vascular endothelial growth factor inhibitors		